Glutamine and cancer - PubMed (original) (raw)

Review

Glutamine and cancer

W W Souba. Ann Surg. 1993 Dec.

Abstract

Objective: This overview on glutamine and cancer discusses the importance of glutamine for tumor growth, summarizes the alterations in interorgan glutamine metabolism that develop in the tumor-bearing host, and reviews the potential benefits of glutamine nutrition in the patient with cancer.

Summary background data: Glutamine is the most abundant amino acid in the blood and tissues. It is essential for tumor growth and marked changes in organ glutamine metabolism are characteristic of the host with cancer. Because host glutamine depletion has adverse effects, it is important to study the regulation of glutamine metabolism in cancer and to evaluate the impact of glutamine nutrition in the tumor-bearing state.

Methods: Data from a variety of investigations on glutamine metabolism and nutrition related to the host with cancer were compiled and summarized.

Results: Numerous studies on glutamine metabolism in cancer indicate that many tumors are avid glutamine consumers in vivo and in vitro. As a consequence of progressive tumor growth, host glutamine depletion develops and becomes a hallmark. This glutamine depletion occurs in part because the tumor behaves as a "glutamine trap" but also because of cytokine-mediated alterations in glutamine metabolism in host tissues. Animal and human studies that have investigated the use of glutamine-supplemented nutrition in the host with cancer suggest that pharmacologic doses of dietary glutamine may be beneficial.

Conclusions: Understanding the control of glutamine metabolism in the tumor-bearing host not only improves the knowledge of metabolic regulation in the patient with cancer but also will lead to improved nutritional support regimens targeted to benefit the host.

PubMed Disclaimer

Similar articles

• Claude H. Organ, Jr. Honorary Lectureship. Glutamine, cancer, and its therapy.
  Klimberg VS, McClellan JL. Klimberg VS, et al. Am J Surg. 1996 Nov;172(5):418-24. doi: 10.1016/s0002-9610(96)00217-6. Am J Surg. 1996. PMID: 8942537
• Glutamine and cancer.
  Medina MA. Medina MA. J Nutr. 2001 Sep;131(9 Suppl):2539S-42S; discussion 2550S-1S. doi: 10.1093/jn/131.9.2539S. J Nutr. 2001. PMID: 11533309 Review.
• Glutamine as indispensable nutrient in oncology: experimental and clinical evidence.
  Kuhn KS, Muscaritoli M, Wischmeyer P, Stehle P. Kuhn KS, et al. Eur J Nutr. 2010 Jun;49(4):197-210. doi: 10.1007/s00394-009-0082-2. Epub 2009 Nov 21. Eur J Nutr. 2010. PMID: 19936817 Review.
• The effects of glutamine-enriched total parenteral nutrition on tumor growth and host tissues.
  Austgen TR, Dudrick PS, Sitren H, Bland KI, Copeland E, Souba WW. Austgen TR, et al. Ann Surg. 1992 Feb;215(2):107-13. doi: 10.1097/00000658-199202000-00003. Ann Surg. 1992. PMID: 1546896 Free PMC article.
• The role of glutamine and glucose analogues in metabolic inhibition of human myeloid leukaemia in vitro.
  Griffiths M, Keast D, Patrick G, Crawford M, Palmer TN. Griffiths M, et al. Int J Biochem. 1993 Dec;25(12):1749-55. doi: 10.1016/0020-711x(88)90303-5. Int J Biochem. 1993. PMID: 8138012

Cited by

• Differential effect of asparagine and glutamine removal on three adenocarcinoma cell lines.
  Pessino G, Lonati L, Scotti C, Calandra S, Cazzalini O, Iaria O, Previtali A, Baiocco G, Perucca P, Tricarico A, Vetro M, Stivala LA, Ganini C, Cancelliere M, Zucchetti M, Guardamagna I, Maggi M. Pessino G, et al. Heliyon. 2024 Aug 3;10(15):e35789. doi: 10.1016/j.heliyon.2024.e35789. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39170541 Free PMC article.
• Targeting fatty acid oxidation enhances response to HER2-targeted therapy.
  Nandi I, Ji L, Smith HW, Avizonis D, Papavasiliou V, Lavoie C, Pacis A, Attalla S, Sanguin-Gendreau V, Muller WJ. Nandi I, et al. Nat Commun. 2024 Aug 3;15(1):6587. doi: 10.1038/s41467-024-50998-3. Nat Commun. 2024. PMID: 39097623 Free PMC article.
• Glutamine deficiency drives transforming growth factor-β signaling activation that gives rise to myofibroblastic carcinoma-associated fibroblasts.
  Mezawa Y, Wang T, Daigo Y, Takano A, Miyagi Y, Yokose T, Yamashita T, Yang L, Maruyama R, Seimiya H, Orimo A. Mezawa Y, et al. Cancer Sci. 2023 Nov;114(11):4376-4387. doi: 10.1111/cas.15955. Epub 2023 Sep 14. Cancer Sci. 2023. PMID: 37706357 Free PMC article.
• Glutamine metabolism in diseases associated with mitochondrial dysfunction.
  Bornstein R, Mulholland MT, Sedensky M, Morgan P, Johnson SC. Bornstein R, et al. Mol Cell Neurosci. 2023 Sep;126:103887. doi: 10.1016/j.mcn.2023.103887. Epub 2023 Aug 15. Mol Cell Neurosci. 2023. PMID: 37586651 Free PMC article. Review.
• Preoperative Glutamine Supplementation in Gastric Cancer-Thrombocyte Phagocytic Activity and Early Postoperative Outcomes.
  Kamocki Z, Matowicka-Karna J, Jurczuk A, Milewska A, Niewinski A, Zareba K, Kedra B. Kamocki Z, et al. Nutrients. 2023 Jun 27;15(13):2911. doi: 10.3390/nu15132911. Nutrients. 2023. PMID: 37447236 Free PMC article.

References

1. 1. JPEN J Parenter Enteral Nutr. 1992 Nov-Dec;16(6 Suppl):83S-87S - PubMed
2. 1. JPEN J Parenter Enteral Nutr. 1992 Nov-Dec;16(6):569-78 - PubMed
3. 1. Surg Oncol. 1992 Apr;1(2):173-82 - PubMed
4. 1. Surg Oncol. 1993;2(3):205-15 - PubMed
5. 1. Science. 1955 Sep 16;122(3168):501-14 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • PubMed Central
  • Wolters Kluwer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program